NLE Psychiatric Disorders — Schizophrenia and Psychotic DisordersSummary

Psychosis is a pathological state in which the individual loses contact with objective reality, characterized by disturbances in thought content (delusions), perception (hallucinations), affect (flattened or inappropriate), and cognition (disorganization). It is not a diagnosis but a symptom cluster that may occur in schizophrenia, mood disorders, substance use, medical conditions, or brief reactive episodes. The client's subjective experience of psychotic symptoms is real and distressing to them, even though the content is not grounded in external reality. Understanding this distinction is critical to therapeutic communication: you validate the emotional experience while gently presenting reality.

Schizophrenia is a chronic, severe psychotic disorder with onset typically in late adolescence to early adulthood (peak onset 18–25 years for males; 25–35 for females). Diagnostic criteria require the presence of at least two psychotic symptoms (delusions, hallucinations, disorganized speech, disorganized/catatonic behavior, or negative symptoms) for a significant portion of a one-month period, with continuous signs of the disturbance persisting for at least six months. Function in one or more major life domains (work, education, self-care, interpersonal relationships) is markedly impaired. Schizophrenia is a neurodevelopmental disorder with genetic predisposition, prenatal/perinatal risks, and environmental stressors contributing to dysregulation of dopamine, glutamate, and other neurotransmitter systems. The course is variable: some clients experience a single episode with full remission; others have recurring exacerbations with residual symptoms; still others have a chronic course with persistent positive and negative symptoms.

The psychotic disorder spectrum includes: (1) Brief Psychotic Disorder—psychotic symptoms lasting less than one month, often precipitated by severe stressors, with good prognosis and complete remission; (2) Schizophreniform Disorder—psychotic symptoms lasting one to six months, intermediate between brief and schizophrenia, often progressing to schizophrenia but sometimes resolving; (3) Schizoaffective Disorder—schizophrenic symptoms concurrent with a major mood episode (depression or mania), requiring both psychotic and mood components for diagnosis; (4) Delusional Disorder—fixed, non-bizarre delusions (e.g., being followed, poisoned, infidelity) lasting at least one month without prominent hallucinations or other schizophrenic symptoms, and without marked functional impairment outside the delusional theme; (5) Substance/Medication-Induced Psychotic Disorder and Psychotic Disorder Due to Medical Condition—psychotic features attributable to drugs (stimulants, hallucinogens, corticosteroids) or organic causes (infection, autoimmune, neurological, endocrine). Distinguishing among these is crucial for treatment selection and prognostic counseling.

Positive symptoms represent an 'addition' to normal experience—things that should not be present. (1) Hallucinations are false sensory perceptions without external stimulus, experienced in any sensory modality but auditory hallucinations (hearing voices) are most common in schizophrenia. Command hallucinations direct the client to perform actions, sometimes harmful ones, and represent a high-risk safety concern requiring immediate assessment and intervention. Visual hallucinations, especially of threatening figures, are also significant. (2) Delusions are fixed, false beliefs maintained despite contradictory evidence; they are not explained by the client's culture or education. Common types include persecutory delusions (belief that one is being harassed, spied on, or plotted against), grandiose delusions (belief in special powers, wealth, or importance), referential delusions (belief that incidental events refer to oneself), somatic delusions (belief in bodily dysfunction or infestation), and thought disorder delusions (belief that thoughts are inserted, broadcast, or stolen). (3) Disorganized speech and thought processes present as loose associations (topic shifts without logical connection), tangentiality (answering questions tangentially, never returning to the point), flight of ideas, word salad (incoherent word combinations), neologisms (invented words), and blocking (sudden cessation of thought/speech). (4) Disorganized or bizarre behavior includes agitation, catatonia (mutism, rigidity, waxy flexibility), psychomotor retardation, or actions that appear motivated by psychotic content (undressing to escape 'poison,' speaking to unseen persons).

Negative symptoms represent a 'subtraction' from normal emotional and behavioral function—a poverty of speech, affect, motivation, or pleasure. The classic mnemonic is the five A's: (1) Affective Flattening or Blunted Affect—reduction or absence of emotional expression, such that the client's face, voice, and gestures appear dull and unresponsive even in emotionally charged situations; speech may be monotonous. (2) Alogia—poverty of speech; the client speaks very little, responding to questions with brief, laconic answers or 'I don't know,' giving the impression of limited thoughts. (3) Avolition—marked lack of motivation for goal-directed activities, apathy, and inability to initiate or sustain self-care, work, or social engagement; the client may sit for hours without motivation, even when opportunities for activity are available. (4) Anhedonia—inability to experience pleasure from previously enjoyable activities; food, social interaction, sex, and hobbies feel empty or joyless. (5) Asociality—social withdrawal, preference for isolation, and reduced capacity for forming relationships or engaging in social reciprocity. These symptoms are often more disabling and socially stigmatizing than positive symptoms because they impair the client's ability to work, study, maintain relationships, and participate in community life. Unlike positive symptoms, negative symptoms develop insidiously and persist even when positive symptoms are controlled.

The dopamine hypothesis posits that schizophrenia involves dysregulation of dopamine, with hyperactivity in mesolimbic pathways (reward, emotion, limbic areas) driving positive symptoms (hallucinations, delusions, agitation) and hypoactivity in prefrontal mesocortical pathways contributing to negative symptoms and cognitive impairment. Dopamine D2 receptor blockade in mesolimbic areas reduces positive symptoms, but D2 blockade in nigrostriatal areas causes extrapyramidal side effects, and blockade in tuberoinfundibular areas causes hyperprolactinemia. This model explains why dopamine-blocking antipsychotics are effective: they reduce hyperactive mesolimbic dopamine signaling. However, the model is incomplete; schizophrenia also involves glutamate (reduced NMDA receptor function), serotonin, GABA, and neuropeptide systems, plus structural and functional brain abnormalities (enlarged ventricles, reduced gray matter in temporal lobes, disrupted white matter connectivity). Environmental stressors, prenatal/perinatal complications, substance use (especially cannabis in adolescence), and trauma can precipitate psychosis in genetically vulnerable individuals by further dysregulating dopamine and stress hormones (cortisol, HPA axis). Understanding neurobiology explains both medication efficacy and side effects, informing client and family education about the biologically based nature of schizophrenia (reducing stigma) and the rationale for sustained treatment.

When a client is experiencing hallucinations, therapeutic communication follows these evidence-based principles: (1) Ask directly about the hallucinations—'Are you hearing voices? What are they saying? Are they telling you to hurt yourself or others?'—to assess content, command potential, and distress level. This is not suggesting hallucinations but obtaining critical safety information. (2) Do not argue that the hallucinations are not real ('You're not hearing voices,' 'That's not true'); arguing entrenches the experience and damages rapport. Instead, acknowledge the client's experience as real to them while stating your own reality: 'I don't hear the voices, but I understand you find them frightening. Let's talk about what you're experiencing.' (3) Do not reinforce or agree with the content ('Yes, people are plotting against you'); agreement validates delusions and may escalate paranoia or distress. (4) Help the client develop reality-testing and coping strategies: 'What usually helps when you hear the voices? Can you talk to me instead of listening to them? Would headphones with music help?' (5) Reduce environmental stimuli (noise, shadows, unfamiliar faces) that may heighten perceptual distortions. (6) Maintain a calm, non-threatening demeanor and clear, concrete speech. (7) If hallucinations are distressing or driving dangerous behavior, report to the provider for medication adjustment. (8) Recognize that the client's response to internal stimuli may appear as if they are not listening to you, engaging in soliloquy, or responding to unseen persons; this is not willful inattention but a symptom requiring patience and frequent, brief, reality-oriented contacts.

When a client holds a delusion, the nursing approach differs slightly from hallucination management: (1) Do not argue with the delusion ('That's not true,' 'No one is following you') because arguing is futile, strengthens the client's conviction, and damages rapport. Delusions are protected from logic by their psychological function—they provide an explanation for the client's anxiety or distress, so rational argument fails. (2) Do not agree with or validate the delusional content ('Yes, the CIA is after you'); agreement reinverts the delusion and may escalate paranoia or action based on the false belief. (3) Instead, acknowledge the underlying feeling and emotion: 'It must be very frightening to believe someone wants to harm you. That sounds distressing.' Focus on the affect, not the content. (4) Gently offer alternative explanations grounded in reality: 'I understand you believe that. I don't share that belief, but I'm concerned about how frightened you are. Let's focus on keeping you safe.' (5) Redirect to reality-based topics and activities: encourage structured engagement, reality-focused conversation, and problem-solving about concrete issues (hygiene, meals, activities). (6) Be consistent, honest, and reliable; build trust through predictable, non-judgmental presence. A therapeutic relationship with a delusional client takes time; you cannot 'talk them out of' the delusion, but you can offer a secure relationship and facilitate medication adjustment that will gradually reduce the delusion's salience. (7) Document the specific content and any command delusions directing self-harm or aggression, as these are safety risks. (8) Recognize that paranoid delusions may make the client wary of care; move slowly, respect boundaries, explain all procedures, and avoid sudden movements or invasive contact that could be misconstrued as harmful.

Safety is the highest priority in Maslow's hierarchy and is paramount in schizophrenia care. Assessment focuses on: (1) Command hallucinations—does the client hear voices directing self-harm or harm to others? What are they saying? Can the client resist? This is the most critical safety question because acting on command hallucinations is a leading cause of violence in psychotic illness. (2) Delusional content—what are the client's beliefs? Are they paranoid, grandiose, or somatic? Do the delusions drive action (e.g., a client believing they are contaminated may refuse meals or medication; a client with erotomania may pursue a perceived 'love interest')? (3) Suicidality and self-harm—clients with schizophrenia have a 10% lifetime suicide risk, elevated by depression, hopelessness, and despair following awareness of their illness. (4) Aggression and violence—assess recent history, triggers, and current ideation. Violence risk is increased by comorbid substance use, paranoid delusions, command hallucinations, history of violence, and poor impulse control. (5) Neglect of self-care and medical needs—clients with severe negative symptoms may not eat, drink, or take medications, leading to malnutrition, dehydration, and medical complications. (6) Vulnerability to exploitation—clients with psychosis may be susceptible to victimization, abuse, or manipulation by others. (7) Response to internal stimuli—if the client is clearly responding to hallucinations or delusions, they may not be attending to environmental hazards, leaving them vulnerable to accidents. Nursing interventions include: ensuring a safe environment (reduce hazardous objects), providing adequate staffing and observation appropriate to the risk level (1:1 or close monitoring if high risk), involving the interprofessional team, notifying the provider of safety concerns, and implementing therapeutic measures to reduce distress. If risk of harm is imminent, hospitalization and involuntary treatment under Philippine mental health law may be necessary to protect the client and community.

Typical or first-generation antipsychotics work by blocking dopamine D2 receptors in the brain. Examples include high-potency agents (haloperidol, fluphenazine, perphenazine) and low-potency agents (chlorpromazine, thioridazine). (1) Efficacy: Typicals are highly effective for positive symptoms (hallucinations, delusions, agitation, disorganized behavior), with noticeable improvement often within 1–2 weeks, though full benefit may take 4–6 weeks. They are less effective for negative symptoms and cognitive impairment. (2) Mechanism: D2 receptor blockade in mesolimbic and mesocortical pathways reduces positive symptoms. However, blockade in the nigrostriatal pathway (motor control) causes extrapyramidal side effects, blockade in the tuberoinfundibular pathway (pituitary) causes hyperprolactinemia, and blockade in the chemoreceptor trigger zone causes antiemetic effects (useful but potentially masking other conditions). (3) Side effect profile varies by potency: High-potency agents (haloperidol, fluphenazine) cause more extrapyramidal side effects (acute dystonia, akathisia, pseudoparkinsonism, tardive dyskinesia) but fewer anticholinergic effects and less sedation. Low-potency agents (chlorpromazine) cause more anticholinergic effects (dry mouth, blurred vision, urinary retention, constipation), orthostatic hypotension, sedation, and photosensitivity, but fewer EPS. (4) Dosing: Typicals are usually dosed once or twice daily; long-acting depot formulations (haloperidol decanoate, fluphenazine decanoate, given IM every 2–4 weeks) are available to improve adherence for clients who struggle with daily oral medications. (5) Cost: Typicals are inexpensive and widely available, making them accessible in resource-limited settings like the Philippines. However, their high EPS burden has shifted first-line preference to atypicals in many settings.

Atypical or second-generation antipsychotics block D2 receptors and serotonin 5-HT2A receptors, providing a different mechanism and side effect profile than typicals. Common agents include risperidone, olanzapine, quetiapine, clozapine, aripiprazole, ziprasidone, and paliperidone. (1) Efficacy: Atypicals treat positive symptoms comparably to or slightly less than typicals but are significantly more effective for negative symptoms, cognitive impairment, and mood symptoms (especially in schizoaffective disorder). They are generally considered first-line for schizophrenia. (2) Mechanism: By blocking both dopamine and serotonin, atypicals may achieve symptom control with less dopamine blockade, reducing EPS. However, the mechanism is not fully understood, and individual agent variability is high. (3) EPS profile: Atypicals cause fewer EPS than typicals overall, especially fewer tardive dyskinesia. However, some atypicals (risperidone, paliperidone at higher doses) retain significant EPS risk, particularly at higher doses. Quetiapine and clozapine have minimal EPS. (4) Metabolic side effects: A major drawback of atypicals is metabolic syndrome risk—weight gain, hyperglycemia, diabetes, and dyslipidemia. Olanzapine and clozapine carry the highest metabolic risk; aripiprazole and ziprasidone have lower risk. This requires monitoring of weight (monthly initially, then quarterly), fasting glucose or HbA1c, and lipid panel at baseline and at intervals during therapy. (5) Other side effects: Hyperprolactinemia (galactorrhea, menstrual changes, sexual dysfunction, especially with risperidone and paliperidone); sedation (quetiapine, olanzapine); orthostatic hypotension (especially with clozapine); prolonged QT interval (ziprasidone, thioridazine); seizure lowering of threshold; anticholinergic effects; photosensitivity. (6) Dosing: Most atypicals are dosed once or twice daily orally; long-acting intramuscular formulations are available (risperidone, paliperidone, aripiprazole) for adherence support. (7) Cost: Atypicals are more expensive than typicals, which may limit access in low-income settings; generic formulations are increasingly available.

Clozapine is a unique atypical antipsychotic reserved for treatment-resistant schizophrenia (failure of two or more adequate antipsychotic trials). It is the most effective antipsychotic for both positive and negative symptoms and for suicidality in schizophrenia, but it carries a serious and potentially fatal risk of agranulocytosis—a precipitous drop in white blood cells (especially neutrophils), leaving the client vulnerable to life-threatening infections. Agranulocytosis occurs in 0.5–1% of clozapine-treated clients, typically within the first 3 months but possible at any time. (1) Mandatory monitoring: Clozapine requires regular white blood cell (WBC) and absolute neutrophil count (ANC) monitoring—weekly for the first 6 months, then bi-weekly, then monthly once counts stabilize. If ANC drops below 1,500 cells/μL (or WBC below 3,000), clozapine is discontinued. The client must undergo blood draws despite any inconvenience or reluctance; this is non-negotiable. (2) Client and family education: Teach the client to report signs of infection immediately—fever >38°C, sore throat, mouth ulcers, swollen lymph nodes, or flu-like symptoms. These may signal agranulocytosis and require urgent blood work and possible hospitalization. (3) Dosing: Clozapine is initiated at low doses (12.5–25 mg daily) and titrated slowly (25–100 mg increments every few days to weekly) to minimize orthostatic hypotension and seizure risk. Therapeutic doses are usually 300–600 mg daily in divided doses. (4) Other serious side effects: Beyond agranulocytosis, clozapine carries risks of myocarditis (inflammation of heart muscle, can be fatal, usually early in therapy), cardiomyopathy, severe constipation (impaction, ileus), seizures (dose-dependent), orthostatic hypotension, severe anticholinergic effects, and significant metabolic effects. Baseline ECG and cardiac assessment are recommended; monitor for chest pain, palpitations, or shortness of breath. (5) Adherence: Despite these monitoring demands, clozapine has superior efficacy for resistant cases and potential for life-changing improvement; the benefits often justify the burden when other agents have failed.

Acute dystonia is a severe, sudden-onset extrapyramidal reaction characterized by involuntary, sustained muscle contractions causing painful spasms and abnormal postures. It occurs most commonly with high-potency typical antipsychotics (haloperidol, fluphenazine) but can occur with any dopamine antagonist, especially in young males. (1) Onset: Acute dystonia typically develops within hours to days of starting an antipsychotic or increasing the dose, though it can occur anytime during therapy. It is NOT dose-dependent; it may occur at standard doses. (2) Clinical presentation: Dystonic spasms commonly affect the neck (torticollis—twisted or drawn neck), face (grimacing, lip retraction), jaw (trismus, clenched jaw), tongue (protrusion), eyes (oculogyric crisis—eyes rolling upward uncontrollably, often described as 'eyes locked in the ceiling'), back (opisthotonos—arching backward), or extremities. The spasms are painful and terrifying, often lasting minutes to hours. (3) Laryngeal dystonia—a medical emergency: Dystonia can affect the larynx and pharynx, causing airway obstruction, stridor, or difficulty swallowing. This is a medical emergency that can be fatal if not treated rapidly. (4) Pathophysiology: Acute dystonia results from acute dopamine blockade in the basal ganglia, which disrupts the balance between dopamine and acetylcholine; the relative excess of acetylcholine drives the dystonic reaction. (5) Nursing assessment: Observe for dystonic postures, listen to the client's report of muscle tension or spasms, and ask about recent medication changes. A client in acute dystonia is often frightened and in pain. (6) Nursing interventions: Provide calm reassurance that this is a known, treatable side effect. Position the client safely (avoid falls or further injury). Immediately notify the provider. (7) Treatment: Acute dystonia is treated promptly with parenteral anticholinergic medication—benztropine (Cogentin) 1–2 mg IM/IV or diphenhydramine 25–50 mg IM/IV. Relief is usually rapid (within 5–15 minutes), which is both therapeutic and reassuring to the terrified client. (8) Prevention: For clients at high risk (young males, previous dystonia, high-potency typicals), prophylactic anticholinergics (benztropine 1–2 mg daily) may be prescribed at the start of antipsychotic therapy.

Beyond acute dystonia, three additional extrapyramidal syndromes are important: (1) AKATHISIA—motor restlessness, an irresistible urge to move, experienced as an internal feeling of tension, agitation, or anxiety. The client cannot sit still, paces continuously, shifts weight frequently, and reports feeling jittery or 'driven.' It is easily mistaken for worsening psychotic agitation or anxiety, leading to inappropriate dose increases (which worsen akathisia). Onset is within days to weeks. Akathisia is intensely subjective and distressing; some clients report suicidal ideation when akathisia is severe, suggesting it may be a risk factor for antipsychotic-related suicide. Management includes dose reduction, switching to an atypical, or adding a beta-blocker (propranolol 20–40 mg twice daily) or benzodiazepine. Unlike acute dystonia, akathisia does not respond reliably to anticholinergics. (2) PSEUDOPARKINSONISM—drug-induced Parkinson syndrome, mimicking idiopathic Parkinson disease. It includes tremor (fine, resting, pill-rolling tremor of the fingers), muscle rigidity (lead-pipe rigidity—constant, uniform resistance to passive movement; cogwheel rigidity—jerky, ratchet-like sensation), bradykinesia (slow movement, slow speech, shuffling gait), mask-like face (reduced facial expression), and drooling. It develops over days to weeks. Pseudoparkinsonism responds well to anticholinergics (benztropine 1–2 mg one to three times daily; trihexyphenidyl; or amantadine). (3) TARDIVE DYSKINESIA (TD)—late-onset, potentially permanent involuntary movement disorder. It develops after months to years of antipsychotic exposure (median onset 2–3 years, but can occur sooner and may persist indefinitely after medication discontinuation). TD involves involuntary, repetitive movements of the face and mouth—lip smacking, puckering, chewing, tongue protrusion or rolling, grimacing, blinking—and sometimes of the limbs and trunk (rocking, fidgeting). It is often more socially disabling than positive symptoms because it is visible and stigmatizing. Pathophysiology is unclear but may involve dopamine receptor supersensitivity after chronic blockade. Risk factors include older age, female sex, history of prior EPS, high-potency typicals, long duration of treatment, and high cumulative dose. (4) Management of TD: Prevention is the key because no reliable treatment exists. Strategies include: use the lowest effective antipsychotic dose, consider early switching to atypical agents (which have lower TD risk), and perform regular assessments using validated tools (Abnormal Involuntary Movement Scale, AIMS—examine face, extremities, trunk for abnormal movements; the client is assessed at rest, with eyes open and closed, and during purposeful movement). If TD develops, the offending agent should be reduced or switched (often to an atypical or to clozapine, which may reduce TD). Anticholinergics do NOT help TD and may worsen it—a critical point on NLE exams.

Neuroleptic malignant syndrome (NMS) is a rare but life-threatening reaction to antipsychotics, occurring in 0.01–0.02% of exposed clients. It is more common with high-potency typicals (haloperidol, perphenazine) but can occur with any antipsychotic, including atypicals, and occasionally with metoclopramide or other dopamine antagonists. NMS is NOT simply dose-dependent; it occurs unpredictably in some individuals and is a medical emergency requiring immediate recognition and intervention. (1) Cardinal features (the tetrad)—all four are present in classic NMS: (a) HYPERTHERMIA—high fever, often rapidly rising to 38–40°C or higher, sometimes exceeding 41°C, presenting a risk of seizures, rhabdomyolysis, and multiorgan failure; (b) SEVERE MUSCLE RIGIDITY—'lead-pipe' rigidity, uniform and constant resistance to passive movement, affecting all muscle groups including the masseter, jaw, and back muscles, often accompanied by tremor; (c) AUTONOMIC INSTABILITY—labile and often elevated blood pressure, tachycardia (HR often >110 bpm), tachypnea, profuse diaphoresis (sweating), and sometimes arrhythmias; (d) ALTERED MENTAL STATUS—confusion, disorientation, delirium, stupor, or coma, with fluctuating consciousness. (2) Onset and course: NMS typically develops within 24–72 hours of starting an antipsychotic or increasing the dose, but can develop later. If not treated, it can progress to life-threatening complications within hours to days. (3) Laboratory findings: (a) Marked elevation of creatine kinase (CK)—often 500–3,000 IU/L or higher, sometimes >10,000 IU/L, reflecting skeletal muscle breakdown; (b) Leukocytosis (elevated WBC); (c) Elevated liver enzymes; (d) Elevated myoglobin and myoglobinuria (dark-colored urine from myoglobin in urine); (e) Acute kidney injury from rhabdomyolysis and myoglobin precipitation in renal tubules. (4) Differential diagnosis is critical: NMS must be distinguished from serotonin syndrome (caused by serotonergic drugs—SSRIs, MAOIs, meperidine, tramadol—and characterized by hyperreflexia, clonus, mydriasis, GI symptoms rather than lead-pipe rigidity and hyperthermia as the dominant features), malignant hyperthermia (genetic anesthetic reaction), thyroid storm, infection, or other causes of hyperthermia and rhabdomyolysis. The presence of lead-pipe rigidity, the temporal relationship to antipsychotic exposure, and the absence of clonus or hyperreflexia support NMS over serotonin syndrome. (5) Nursing assessment: Monitor vital signs closely, watch for rapidly rising temperature, assess muscle rigidity (passive movement), assess mental status, monitor for dark urine (myoglobinuria) and oliguria (renal failure), check CK and renal function. A client with unexplained fever + rigidity + autonomic changes on antipsychotics is NMS until proven otherwise.

Once NMS is suspected or diagnosed, management is a medical emergency involving the full interprofessional team and intensive monitoring: (1) STOP the antipsychotic immediately—discontinuing the offending agent is the primary intervention. If the client is in critical condition, treatment cannot wait for the medication to be cleared; supportive care and specific agents must be given simultaneously. (2) AGGRESSIVE COOLING—because hyperthermia is the most immediately life-threatening feature: place the client in a cool room, use cooling blankets or ice packs to the groin and axillae (major vessels), remove excess clothing, apply cool water mists, offer cold oral fluids if conscious. Goal core temperature is <38.5°C. (3) HYDRATION AND RENAL PROTECTION—aggressive IV hydration (often 1–2 L/hour or more) to maintain urine output of 200 mL/hour or more. This dilutes myoglobin and prevents precipitation in renal tubules (myoglobin-induced acute tubular necrosis). Monitor intake and output strictly, check urine color (myoglobinuria appears as dark brown or cola-colored urine), and monitor serum creatinine and potassium (hyperkalemia from rhabdomyolysis can cause fatal arrhythmias). Insert a Foley catheter for accurate monitoring. (4) PHARMACOLOGICAL MANAGEMENT: (a) DANTROLENE (Dantrium)—a muscle relaxant that acts on the sarcoplasmic reticulum in skeletal muscle to inhibit calcium release, reducing muscle rigidity and heat production. Initial dose is 1–2.5 mg/kg IV push, repeated every 5–10 minutes up to a maximum cumulative dose of 10 mg/kg. After the crisis resolves, dantrolene may be continued orally 4–8 mg/kg daily in divided doses for 24–48 hours to prevent recurrence. (b) BROMOCRIPTINE (Parlodel)—a dopamine agonist that may counteract the pathological dopamine blockade. Typical dose is 2.5–5 mg orally (or via NG tube if the client is unable to swallow) three times daily, continued for 24–48 hours after resolution. (5) SUPPORTIVE CARE: Place on continuous cardiac monitoring (watch for arrhythmias from hyperthermia, hyperkalemia, or rhabdomyolysis), maintain airway and oxygen, place on NPO status (aspiration risk with altered mental status), ensure adequate oxygenation and ventilation (patients may develop respiratory complications from rhabdomyolysis and acidosis), and monitor electrolytes hourly initially (especially potassium; hyperkalemia >6 mEq/L is life-threatening and may require insulin + dextrose, calcium gluconate, or dialysis). (6) MONITORING AND REASSESSMENT: Continue vital sign and laboratory monitoring (CK, myoglobin, creatinine, potassium, and liver enzymes) every 4–6 hours until trending down and the client is clearly recovering. Recovery typically takes 24–72 hours after stopping the antipsychotic and initiating treatment. (7) PREVENTION OF RECURRENCE: Once the client recovers, never re-expose them to the same antipsychotic. If antipsychotic therapy is needed again (for a client with schizophrenia who had NMS with one agent), a different antipsychotic class may be tried after full recovery, but this carries residual risk. Some clinicians avoid all antipsychotics after NMS; others use a different agent at a lower dose with very close monitoring. The risk-benefit discussion must involve the client and family.

Anticholinergic side effects result from dopamine blockade in cholinergic pathways and from anticholinergic medications used to treat EPS. Common anticholinergic effects include: (1) Dry mouth—reduced salivation; counsel the client to sip water frequently, use sugar-free lozenges, chew sugar-free gum, and maintain good oral hygiene. Untreated dry mouth increases the risk of dental caries and oral infection. (2) Blurred vision—difficulty focusing, especially on near objects; clients may struggle with reading or recognizing faces. Usually improves with time, but inform the client it is a known effect and may not be dangerous driving (assess carefully). (3) Constipation—reduced GI motility; very common and sometimes severe, especially with clozapine. Assess bowel habits, increase dietary fiber, encourage fluids and activity, and prescribe stool softeners (docusate) or osmotic laxatives (polyethylene glycol, lactulose) as needed. Severe constipation can progress to fecal impaction or ileus, a serious complication. (4) Urinary retention—reduced bladder smooth muscle contraction; client may have difficulty voiding or incomplete emptying. Perform post-void residual checks if retention is suspected; catheterization may be needed. (5) Tachycardia—anticholinergics may increase heart rate; monitor vital signs. (6) Dilated pupils (mydriasis)—increased sensitivity to light. (7) Hyperthermia in hot environments—impaired sweating increases the risk of heat stroke in tropical climates like the Philippines. Counsel the client to avoid extreme heat, stay hydrated, and use cooling strategies (fans, light clothing, air conditioning). This is particularly important for Filipino clients living in hot, humid climates. (8) Cognitive effects—especially in older adults: confusion, memory impairment, delirium if anticholinergic burden is high. Limit anticholinergic use in older clients. (9) Glaucoma worsening—in clients with narrow-angle glaucoma, anticholinergics can precipitate an acute glaucoma attack; screen for glaucoma history and counsel the client to report eye pain, halos, or vision changes. (10) Managing anticholinergic burden: Some antipsychotics inherently have anticholinergic properties; adding separate anticholinergic medications for EPS increases the total burden. Consider alternatives: akathisia may respond to beta-blockers instead of anticholinergics; pseudoparkinsonism might improve with dose reduction or switching to an atypical; modern practice favors reducing anticholinergic use in older adults.

Beyond EPS and anticholinergic effects, antipsychotics carry several other significant adverse effects: (1) METABOLIC EFFECTS—particularly with atypicals: (a) Weight gain—often substantial (5–15 kg or more), especially with olanzapine and clozapine; due to increased appetite, reduced energy expenditure, and altered glucose metabolism. Clients may become self-conscious, withdraw socially, or stop medication. (b) Hyperglycemia and diabetes—new-onset type 2 diabetes occurs in 1–2% of clozapine users (compared to population baseline); risk increases with family history, obesity, and metabolic syndrome. (c) Dyslipidemia—elevated triglycerides and total cholesterol. (2) These metabolic effects contribute to premature cardiovascular death, a major cause of excess mortality in schizophrenia. Nursing interventions include baseline and periodic monitoring of weight (monthly), fasting glucose or HbA1c, lipid panel, and blood pressure; counseling about diet (reduce high-calorie, high-sugar foods), exercise, and smoking cessation; and considering switching to an agent with lower metabolic risk if the client develops significant metabolic changes. (3) HYPERPROLACTINEMIA—increased prolactin due to dopamine blockade in the tuberoinfundibular pathway (dopamine normally inhibits prolactin). Effects include: (a) Galactorrhea (lactation in non-pregnant individuals, males and females); (b) Menstrual irregularities, amenorrhea, or infertility in females; (c) Sexual dysfunction (decreased libido, erectile dysfunction, delayed orgasm) in males and females; (d) Gynecomastia (breast tissue enlargement in males). These effects are particularly bothersome to young clients and can reduce adherence. Risperidone and paliperidone carry the highest hyperprolactinemia risk; aripiprazole may actually lower prolactin. If hyperprolactinemia is severe, switching to an agent with lower prolactin effect or adding dopamine agonist (bromocriptine) may be considered. (4) CARDIOVASCULAR EFFECTS: (a) Orthostatic hypotension (especially with clozapine and low-potency typicals)—postural drop in blood pressure causing dizziness, syncope, and fall risk. Counsel the client to rise slowly, sit on bed edge before standing, and report dizziness. (b) QT prolongation (especially with ziprasidone, thioridazine, older agents)—baseline ECG is recommended, and caution is advised in clients with QT prolongation, electrolyte abnormalities, or cardiac disease. (5) SEIZURE THRESHOLD—all antipsychotics lower the seizure threshold; clozapine carries the highest risk (1–2% seizure incidence). Clients with a seizure disorder require careful monitoring; baseline EEG may be considered, and anticonvulsant prophylaxis may be needed. (6) PHOTOSENSITIVITY—risk of severe sunburn; counsel the client to use high-SPF sunscreen, wear protective clothing, and limit sun exposure. This is important in tropical climates. (7) SEDATION—especially with quetiapine and clozapine, and with low-potency typicals. May impair work or academic performance; adjust dosing if possible (give larger dose at bedtime). (8) RESPIRATORY EFFECTS with clozapine—myocarditis and cardiomyopathy, though rare, are serious, particularly early in therapy. Baseline ECG and troponin are recommended; monitor for chest pain, palpitations, or shortness of breath.

Medication adherence is one of the most significant challenges in schizophrenia treatment. Studies show that 40–60% of clients with schizophrenia have poor adherence in the first year; non-adherence is the leading cause of relapse and hospitalizations. Understanding the barriers to adherence and implementing strategies to overcome them are critical nursing roles. (1) BARRIERS TO ADHERENCE: (a) Side effects—EPS, weight gain, sedation, sexual dysfunction, and anticholinergic effects are major reasons clients stop medications. (b) Lack of insight—many clients with schizophrenia lack awareness of their illness (anosognosia) and do not believe they need medication. (c) Substance use—comorbid alcohol or drug use increases relapse risk and medication non-adherence. (d) Stigma—clients may be ashamed to take psychiatric medication or have internalized stigma. (e) Cost—medications are expensive, especially atypicals. (f) Complexity of regimen—multiple daily doses are harder to remember than once-daily dosing. (g) Social disorganization—homelessness, poverty, and lack of family support reduce adherence. (h) Negative attitudes of providers or family—if a provider or family member conveys that the client 'should' be able to control symptoms without medication, the client may attempt to stop. (2) NURSING STRATEGIES TO SUPPORT ADHERENCE: (a) Psychoeducation—explain the brain biology of schizophrenia and how antipsychotics work; help the client understand that medication is essential for managing the disorder, not an optional 'crutch.' Use analogies (e.g., 'Antipsychotics work on the brain like insulin works on the pancreas in diabetes'). (b) Regular side effect monitoring and intervention—assess side effects at each visit, reassure the client that many are manageable, offer coping strategies, and involve the provider in switching agents or adjusting doses if side effects are severe. (c) Simplified regimen—advocate for once-daily dosing if possible; if the client struggles with daily adherence, discuss long-acting injectable (LAI) formulations (given IM every 2–4 weeks), which remove the daily adherence burden and allow early detection of non-adherence (the client comes for injection or doesn't). (d) Involve family and support network—family support improves adherence; include the family in education and planning. (e) Relapse signature identification—work with the client and family to identify early warning signs of relapse (increasing suspiciousness, sleep disturbance, withdrawal, social isolation, stress) so that early intervention (medication adjustment, hospitalization if needed) can prevent full relapse. (f) Community mental health support—connect the client to assertive community treatment (ACT), case management, peer support, and other community resources that improve engagement and adherence. (g) Address comorbid substance use—if the client uses alcohol or drugs, this must be addressed for adherence to improve. (h) Discuss values and goals—regularly check in about the client's hopes, goals, and values; medication should enable the client to pursue goals (work, education, relationships, spirituality), not just suppress symptoms.

The Philippine Mental Health Act (Republic Act No. 11036, enacted 2018) is landmark legislation that fundamentally shifts mental health care in the Philippines from hospital-centered to community-based, recovery-oriented, and rights-protective. Key principles include: (1) RECOVERY-ORIENTED CARE—mental illness is not viewed as a life sentence or permanent disability. Recovery involves managing symptoms while pursuing meaningful roles, relationships, and goals. Clients are active partners in their treatment plan, not passive recipients. (2) RIGHTS-BASED CARE—persons with mental illness have the right to: (a) Accurate diagnosis and appropriate treatment; (b) Information about their condition and treatment options, and informed consent; (c) Confidentiality and privacy; (d) Dignity, freedom from stigma and discrimination; (e) Participation in decisions about their care; (f) Least restrictive treatment (hospitalization is a last resort, not the default); (g) Access to mental health services. Involuntary admission and involuntary treatment are permitted only when there is a serious threat to self or others, cannot be managed in less restrictive settings, and must be reviewed regularly. (3) COMMUNITY-BASED CARE—the goal is to keep clients in their communities, with family and support networks, rather than institutionalizing them. This requires development of community mental health clinics, primary health care integration (mental health screening and basic care in barangay health centers), peer support programs, family support groups, and crisis intervention teams. (4) INTEGRATION WITH PRIMARY HEALTH CARE—mental health is integrated into the general health system, not siloed. PHWs (public health workers) and BHWs (barangay health workers) are trained to screen for mental illness, provide basic psychoeducation, distribute medications (with supervision), and refer complex cases to mental health specialists. This model reaches underserved rural areas. (5) ADDRESSING STIGMA—the law mandates anti-stigma campaigns, media training, workplace mental health policies, and integration of mental health content into school curricula. Reducing stigma is essential because it prevents help-seeking and increases non-adherence. (6) PSYCHOSOCIAL SUPPORT—mental health care is not medication-only. Vocational rehabilitation, peer support groups, family psychoeducation, and cognitive-behavioral therapy are recognized and supported. (7) ROLE OF NURSES—nurses are key mental health providers in the community. BSN graduates working in the Philippines will likely work in primary health care settings, community mental health clinics, or rural hospitals, where they will screen for psychotic symptoms, counsel clients and families, distribute medications, and refer for specialist evaluation. BSN graduates in psychiatric settings will lead multidisciplinary teams implementing recovery-oriented, community-linked care.

A comprehensive psychiatric assessment for a suspected psychotic disorder includes: (1) PRESENTING PROBLEM AND HISTORY OF PRESENT ILLNESS—When did symptoms start? What prompted the client to seek help or present to the hospital? Is there a stressor (job loss, relationship breakup, substance use, trauma, medical illness)? What is the timeline of symptom progression? (2) HISTORY OF PSYCHOTIC SYMPTOMS—Has the client experienced delusions, hallucinations, disorganized speech, or bizarre behavior before? What was the course of symptoms in previous episodes? (3) PAST PSYCHIATRIC HISTORY—Previous diagnoses, hospitalizations, suicide attempts, medication trials (what worked, what caused side effects). (4) SUBSTANCE USE HISTORY—Current and past use of alcohol, cannabis, stimulants, or hallucinogens; timing of use relative to symptom onset (substance-induced psychosis vs. primary psychotic disorder). (5) MEDICAL HISTORY—Neurological conditions (seizures, head injury, stroke), endocrine disorders (thyroid), infections, autoimmune conditions, and medications (steroids, stimulants, dopamine agonists) that can induce psychosis. (6) FAMILY HISTORY—Schizophrenia, other psychiatric illnesses, suicide, substance use disorders; this informs genetic risk. (7) MENTAL STATUS EXAMINATION—Appearance (dress, grooming, overall presentation); Behavior (psychomotor activity, aggression, eye contact, response to internal stimuli); Speech (rate, volume, coherence, articulation); Mood and Affect (self-reported mood, observed affect, appropriateness, stability); Thought Content (delusions, obsessions, preoccupations, suicidal/homicidal ideation); Thought Process (coherence, logical flow, tangentiality, loose associations); Perception (hallucinations—which sensory modality, content, distress level, command potential); Cognition (orientation, attention, memory, concentration); Insight (does the client recognize something is wrong? Degree of awareness of illness); Judgment (ability to appraise situations and make reasonable decisions). (8) RISK ASSESSMENT—Is the client safe? Suicide risk (hopelessness, command hallucinations to harm self, history of attempts), homicide risk (command hallucinations to harm others, paranoid delusions about specific people, history of violence), risk of self-neglect (refusing food, hygiene, medications), vulnerability to exploitation. (9) FUNCTIONAL ASSESSMENT—How is the client managing work, school, relationships, self-care? Is function acutely impaired or chronically impaired? (10) STRENGTHS AND RESILIENCE—What are the client's coping skills, support systems, previous successful treatments, interests, and values? Recovery is built on strengths.

Using NANDA-I taxonomy, common nursing diagnoses for clients with schizophrenia include: (1) Disturbed Thought Process related to altered neurotransmitter function as evidenced by delusions, loose associations, disorganized speech. Interventions: reality orientation (gentle, non-argumentative), structured activities, cognitive interventions, medication management. (2) Disturbed Sensory Perception (Auditory, Visual) related to altered neurotransmitter function as evidenced by hallucinations. Interventions: ask about hallucinations, do not reinforce, recommend reality-focused activities, suggest coping strategies (music, talking to someone, reality checks). (3) Risk for Self-Harm or Other-Directed Violence related to command hallucinations, paranoid delusions, or poor impulse control. Interventions: assess frequency and content of commands, safety planning, 1:1 observation if high risk, secure environment, medication management. (4) Social Isolation related to negative symptoms, paranoia, or stigma as evidenced by withdrawal, lack of relationships. Interventions: offer frequent brief contacts, involve in structured groups, connect to peer support, family engagement. (5) Self-Care Deficit (bathing, hygiene, grooming, toileting, feeding) related to negative symptoms, disorganization, or lack of motivation. Interventions: provide structure, verbal cueing, assistance, encourage gradual self-care. (6) Ineffective Coping related to stress, delusions, or poor problem-solving skills. Interventions: teach coping skills (relaxation, problem-solving), identify triggers, practice stress management. (7) Ineffective Medication Adherence related to side effects, lack of insight, or disorganization. Interventions: psychoeducation about medication, side effect management, simplified regimens, family support, consider LAI formulations. (8) Interrupted Family Processes related to client's illness, caregiver burden, lack of understanding. Interventions: family psychoeducation, support groups, respite care, coping strategies.

The differential response of symptom domains to medication is explained by neurobiology: typical antipsychotics primarily block dopamine and are effective for positive symptoms but less so for negative symptoms and cognitive impairment, which may require atypical agents or psychosocial interventions.

Side effect profiles are directly linked to receptor occupancy patterns and anatomical pathways affected. Understanding this mechanism helps predict which agents will cause EPS and informs choices for clients with prior EPS or high EPS risk.

The pathophysiology (acetylcholine excess in some pathways, but dopamine excess in others leading to TD) explains why anticholinergics help some EPS but not others. This relationship is a frequent NLE differentiator.

NMS is a direct consequence of dopamine blockade at multiple CNS sites; the emergency treatment directly targets reversing the dopamine blockade (bromocriptine) or its muscular consequences (dantrolene). This causal link helps students remember treatment priorities.

Recovery in schizophrenia depends on sustained medication use, which is undermined by side effects and psychosocial factors. A holistic approach addressing medication tolerance (side effect management), psychological factors (insight building, reducing stigma), and social factors (family support, community engagement) is most effective.

Communication strategies are not arbitrary 'rules' but flow from understanding the psychology of psychosis: the client's subjective distress is real, argument entrenches symptoms, and a therapeutic relationship enables both safety and treatment acceptance.

The legal and ethical framework set by RA 11036 shapes all subsequent practice decisions: which clients are hospitalized (only imminent danger, cannot be managed in community), how care is coordinated with community resources, and how the nurse respects rights while ensuring safety. This is not just policy but practice-changing.